

Retrotransposition of marked SVA elements by human L1s in cultured cells

Dustin C. Hancks^{1,3}, John L. Goodier^{2,3,†}, Prabhat K. Mandal^{3,†}, Ling E. Cheung³ and Haig H. Kazazian Jr^{2,3,*}

¹Cell and Molecular Biology Graduate Group, The University of Pennsylvania School of Medicine, Philadelphia, PA, USA, ²Department of Pediatrics and ³McKusick-Nathans Institute for Genetic Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA

Received January 28, 2011; Revised and Accepted May 27, 2011

Human retrotransposons generate structural variation and genomic diversity through ongoing retrotransposition and non-allelic homologous recombination. Cell culture retrotransposition assays have provided great insight into the genomic impact of retrotransposons, in particular, LINE-1(L1) and *Alu* elements; however, no such assay exists for the youngest active human retrotransposon, SINE-VNTR-*Alu* (SVA). Here we report the development of an SVA cell culture retrotransposition assay. We marked several SVAs with either neomycin or EGFP retrotransposition indicator cassettes. Engineered SVAs retrotranspose using L1 proteins supplemented *in trans* in multiple cell lines, including U2OS osteosarcoma cells where SVA retrotransposition is equal to that of an engineered L1. Engineered SVAs retrotranspose at 1–54 times the frequency of a marked pseudogene in HeLa HA cells. Furthermore, our data suggest a variable requirement for L1 ORF1p for SVA retrotransposition. Recovered engineered SVA insertions display all the hallmarks of LINE-1 retrotransposition and some contain 5' and 3' transductions, which are common for genomic SVAs. Of particular interest is the fact that four out of five insertions recovered from one SVA are full-length, with the 5' end of these insertions beginning within 5 nt of the CMV promoter transcriptional start site. This assay demonstrates that SVA elements are indeed mobilized *in trans* by L1. Previously intractable questions regarding SVA biology can now be addressed.

INTRODUCTION

Greater than 30% of the human genome has been generated through retrotransposition of LINE elements and other RNA species by the LINE reverse transcriptase (1,2). Retrotransposition is ongoing in human populations as indicated by *de novo* L1 (3), *Alu* (4) and SINE-VNTR-*Alu* (SVA) (5) insertions associated with disease and by the large number of polymorphic insertions (6–12), many of which are at a low allele frequency in human genomes (13). Most of our knowledge regarding human retrotransposons has been accumulated through genomic analyses (1,14–21), cell culture retrotransposition assays (22–36) and mouse models (37–42).

SVAs are hominid specific, generate non-coding RNAs (20) and the youngest active human retrotransposon (5).

SVA insertions are associated with eight cases of single-gene disease (43–50). SVAs are composite elements (Fig. 1A) (51–53) consisting of multiple domains, these being in order from the 5' end: (i) a CCCTCT repeat, (ii) an *Alu*-like domain, (iii) a GC-rich variable number of tandem repeats (VNTRs) and (iv) an *env* gene sequence and right LTR from an extinct HERV-K, referred to as SINE-R (5,20,54). The individual SVA domains are present in the genomes of Old World monkeys (55,56), and assembly of these domains presumably occurred primarily by pre-mRNA splicing sometime after the divergence of hominids from Old World monkeys (57).

SVA genomic insertions contain the hallmarks of L1-mediated retrotransposition, including 5' truncations, inversions, 3' transductions, polyA tails and target-site duplications (TSDs) of varying length flanking the insertion site (5,14–

*To whom correspondence should be addressed at: Johns Hopkins University School of Medicine, Broadway Research Building, 733 N. Broadway RM 439, Baltimore, MD 21205, USA. Tel: +1 4105026660; Fax: +1 4105022006; Email: kazazian@jhmi.edu

†These authors contributed equally.




Figure 1. A cell-culture SVA retrotransposition assay. (A) A full-length 'canonical' SVA in the human genome, with the individual domains in order from 5' to 3'. (i) CCCTCT hexamer; (ii) the *Alu*-like domain consisting of two antisense-spliced *Alu* fragments and a sequence of unknown origin; (iii) VNTR; and (iv) SINE-R (*env* sequence and right LTR from an extinct HERV-K), terminating in a polyA tail (AAA_n), with the entire insertion flanked by a TSD (black horizontal arrows). (B) The SVA.10 *mneoI* construct. A 'master' SVA locus, SVA.10, from the SVA_{F1} (*MAST2*) subfamily containing both 5' (5' TR, *Alu*) and 3' (*Alu*, 3' TR) transductions (TR) marked with the *mneoI* retrotransposition cassette cloned into the pCEP-Pur plasmid backbone. (C) The rationale of the *trans*-complementation assay is illustrated. Only if the SVA containing the *mneoI* reporter undergoes a round of transcription, followed by reverse transcription and integration presumably mediated by a full-length L1 (shown), will the reading frame of the neomycin phosphotransferase reporter be restored, conferring G418 resistance (G418^R). (D) G418^R foci formation is observed in HeLa HA cells when SVA.10 *mneoI* is co-transfected with the highly active L1 driver construct, pcDNA.L1-RP. The mean number of clones per well \pm SEM and the range of clones across the wells are displayed below. The number of wells (*n*) assayed for this experiment is shown. The retrotransposition frequency (mean number of clones/number of transfected cells) for SVA.10 *mneoI* is listed below the range.

16,21,58). However, experimental evidence for mobilization in *trans* by L1 has not been obtained, despite the efforts by a number of laboratories. Here we experimentally demonstrate mobilization of different SVAs in *trans* by highly active human L1s in various cell types.

RESULTS

An SVA retrotransposition assay

Recently, a new human-specific SVA subfamily, SVA_{F1}, characterized by the presence of the first exon from the

	DRIVER	PASSENGER						
		SVA.10 <i>mneoI</i>	SVA.10B <i>mneoI</i>	SVA.2 <i>mneoI</i>	ORF1 <i>mneoI</i>	<i>Alu neo</i> ^{Tet}	SVA.10 <i>neo</i> ^{Tet}	
A	pcDNA.L1-RP 	23.8 +/- 3.2 (29)	3.60 +/- 1.7 (5)	3.1 +/- 0.9 (10)	51.67 +/- 13.48 (9)	93.48 +/- 9.11 (21)	3.30 +/- 1.01 (10)	G418R foci +/- s.e.m. (n)
B	pcDNA.L1.3 	4.3 +/- 0.3 (6)		1.2 +/- 0.3 (6)				G418R foci +/- s.e.m. (n)
C	pcDNA.L1-RP ΔΔ 	0.0 +/- 0.0 (6)		0.0 +/- 0.0 (5)				G418R foci +/- s.e.m. (n)
D	pcDNA.L1-RP (D702Y) 	0.1 +/- 0.1 (10)	0.0 +/- 0.0 (1)	0.0 +/- 0.0 (2)	0.5 +/- 0.5 (2)	0.1 +/- 0.1 (7)	0.0 +/- 0.0 (2)	G418R foci +/- s.e.m. (n)
E	pcDNA.ORF2 	0.5 +/- 0.2 (10)		5.0 +/- 0.4 (4)		123.1 +/- 24.3 (8)	0.0 +/- 0.0 (3)	G418R foci +/- s.e.m. (n)
F	Cep.ORF2 	0.5 +/- 0.2 (6)				96.3 +/- 16.1 (4)		G418R foci +/- s.e.m. (n)
G	pcDNA.L1-RP (N157A/R159G) 	0.0 +/- 0.0 (6)		0.2 +/- 0.2 (6)	40.3 +/- 2.3 (3)			G418R foci +/- s.e.m. (n)

Figure 2. Engineered SVA retrotransposition is mediated by human L1 proteins in HeLa HA cells. Different marked SVAs, ORF1 *mneoI* and *Alu neo*^{Tet} were co-transfected with various drivers (A–G) to determine the role of L1 proteins in SVA retrotransposition. All transfections were carried out in six-well plates with 1.5 μg of the corresponding ‘driver’ plasmid and 0.5 μg of the corresponding ‘passenger’ plasmid. Data are presented as the mean number of G418^R foci per well ± SEM, with the number of replicates (*n*) below each mean. Where no data are presented, it means that the experiment was not carried out. ‘Hot’ L1s, L1-RP and L1.3 mobilize engineered SVAs (A and B). Removal of the CMV and L1 promoter (5′ UTR) from pcDNA.L1-RP reduces SVA foci formation to background levels (C). Different drivers containing point mutations (D and G) or lacking ORF1 coding sequence (E and F) were co-transfected with SVA. (*) indicates the relative location of the engineered point mutation.

MAST2 gene, and lacking the CCCTCT hexamer along with most of the *Alu*-like domain, was described (59–61). One element within this family on CH10 (SVA.10) is thought to be the source element for at least 13 additional insertions based upon the presence of shared 5′ and 3′ transductions (59,60), including one SVA that is the progenitor to a disease-causing insertion (46,59). Likewise, a canonical human-specific SVA on CH2 (SVA.2), classified as an SVA_D, is thought to be the source element for at least nine insertions in the human genome as indicated by the presence of shared 3′ transductions (21). These two elements potentially represent two of the most active SVAs in humans since the human–chimpanzee divergence (21,59,60). Because both of these loci have produced numerous human-specific SVA insertions, we reasoned that both would be appropriate candidates to test for retrotransposition competency in cultured cells. The entire SVA.10 locus, including the 5′ and 3′ transductions was isolated, marked with the *mneoI* retrotransposition indicator cassette (24,62,63) and cloned into pCEP4 vector (Fig. 1B) to make SVA.10 *mneoI*. *mneoI* consists of a backward neomycin resistance gene, relative to SVA, with a SV40 promoter and thymidine kinase polyA signal. The *neo* gene is interrupted by an intron (IVS) in the sense orientation (Fig. 1B). Thus, only upon splicing of an SVA transcript followed by reverse transcription and integration into the genome will G418 resistance (G418^R) be conferred upon the transfected cell (Fig. 1C). Likewise, the entire SVA.2 locus was isolated, but only the SVA sequence was marked with *mneoI*, which differs from SVA.10 *mneoI*, which contains multiple transductions (see Materials and Methods).

To determine whether our constructs were ‘active’ in cell culture and L1 was sufficient for *trans*-mobilization in cultured HeLa HA cells, we transiently co-transfected SVA.10 *mneoI*, referred to here as the ‘passenger’ plasmid, and highly active unmarked L1s, either L1-RP (64) or L1.3 (65,66), which are referred to here as ‘driver’ plasmids into HeLa HA cells (Figs 1D and 2A). SVA passengers were cloned into the replication-competent pCEP4 vector, whereas the L1 drivers were cloned into pcDNA6, a non-replicating plasmid in HeLa HA cells, (i) to enable antibiotic selection for both plasmids if need be, and (ii) to preclude the formation of plasmid recombinants, which had been a difficulty in previous attempts to develop an SVA cell culture retrotransposition assay (unpublished data, E.M. Ostertag, J.L.G. and H.H.K., Jr). We used the HeLa HA cell line because *Alu* displays high levels of L1 *trans*-mobilization in this HeLa strain (25,67) and thus serves as a robust positive control for our *trans*-mobilization assay (Supplementary Material, Figs S1 and S2 and data not shown).

To determine the frequency of SVA.10 *mneoI* retrotransposition, we transiently co-transfected SVA.10 *mneoI* with pcDNA.L1-RP (64) (Figs 1D and 2A). The retrotransposition frequency was calculated as the number of foci divided by the number of transfected cells (see Materials and Methods). The mean number [± standard error of the mean (SEM)] of foci/well for SVA.10 *mneoI* across 12 replicates was 27.8 (± 3.61) (Fig. 1D). The frequency of SVA.10 *mneoI* retrotransposition driven by pcDNA.L1-RP in this assay is 3.35E – 04 events per transfected cell. SVA.10 *mneoI* foci formation was significantly less when driven by pcDNA.L1.3 (4.33 ± 0.33) (Fig. 2B). This corroborates a




Figure 3. (A) Steady-state levels of spliced RNA from marked SVA constructs differ. HeLa cells were co-transfected with pcDNA.L1-RP and different SVA constructs. Northern analysis used a *neo* sense probe spanning the intron. A representative northern blot (10 μ g of total RNA) is shown. Across the top are the names of the different SVA passenger constructs. Along the left side is a size standard in kilobases (kb). Below is the 28S rRNA loading control. The expected RNA lengths derived from the SVA constructs (kb) including spliced *mneoI* from the 5' end of the element to the SV40 polyA signal in pCEP: SVA.10 *mneoI* = 5.5, SVA.10R *mneoI* Δ 3tr = 4.9, SVA.2 *mneoI* = 3.5, *Alu neo*^{Tet} = 1.5. (B) Representative T-75 flasks of *neo* assays carried out are shown. Engineered SVAs or GFP *mneoI* were co-transfected with pcDNA.L1-RP or without driver plasmid (No Driver). Refer to Table 1 for foci counts and relative activity.

previous study which showed that L1-RP is a better driver than L1.3 (23).

Additional replicates were carried out (Fig. 2A) for SVA.10 *mneoI* along with SVA.2 *mneoI* co-transfections with either pcDNA.L1-RP (Fig. 2A) or pcDNA L1.3 (Fig. 2B). SVA.2 *mneoI* was mobilized by pcDNA.L1-RP (3.1 ± 0.91) and pcDNA L1.3 (1.17 ± 0.31) in *trans*. Depending on the driver L1, SVA.10 *mneoI* produces about four to eight times as many foci in HeLa HA cells as SVA.2 *mneoI*. A few nucleotide substitutions introduced during the cloning process in the SVA.10 3' transduction (Supplementary Material, Fig. S2) were identified. Therefore, we recloned the 3' transduction from BAC DNA to make SVA.10B *mneoI*. *Trans*-mobilization assays revealed that SVA.10 *mneoI* produced approximately six times more foci than SVA.10B *mneoI* (23.79 ± 3.19 versus 3.6 ± 1.69) (Fig. 2A). Although the role of these substitutions is unclear, northern analysis indicates that steady-state levels of SVA.10 *mneoI* RNA are significantly greater than those of SVA.10B *mneoI* RNA and a modified SVA.10 construct, SVA.10R *mneoI*, which lacks the 3' transduction (Fig. 3A). In contrast, SVA.2 *mneoI* and *Alu neo*^{Tet} RNA levels appear robust.

To ensure G418^R foci formation represented L1-mediated retrotransposition and not plasmid–plasmid recombination, we co-transfected SVA.10 *mneoI* (Fig. 2C and Supplementary Material, Fig. S1) and SVA.2 *mneoI* (Fig. 2C) with pcDNA.L1-RP $\Delta\Delta$, a modified pcDNA.L1-RP construct lacking both the CMV promoter and the L1 5' UTR. A driver lacking promoter sequences should not generate

G418^R foci, unless (i) recombination occurs between the plasmid lacking the promoter and the plasmid containing the promoter (23) or (ii) endogenous RT activity is utilized. The absence of G418^R colonies (Fig. 2C) indicates that SVA foci are not a product of plasmid–plasmid recombination (23). Occasional foci are observed when *Alu neo*^{Tet} is transfected with pcDNA.L1-RP $\Delta\Delta$ (data not shown). This result is consistent with low levels of RT activity in this cell line and mobilization of *Alu* in the absence of driver L1s (27).

Next, to compare SVA.10 retrotransposition activity with that of *Alu*, we replaced the *mneoI* reporter in SVA.10 *mneoI* with the *neo*^{Tet} retrotransposition indicator cassette (68) and refer to this construct as SVA.10 *neo*^{Tet}. *neo*^{Tet} differs from *mneoI*, in that the *neo* gene is interrupted by a self-splicing group 1 intron instead of a nuclear mRNA intron. SVA.10 *neo*^{Tet} transfection with pcDNA.L1-RP resulted in 3.3 ± 1.01 foci per well, which corresponds to approximately 1/30 the number of foci produced when *Alu neo*^{Tet} is transfected with the same L1 driver (93.5 ± 9.1 , Fig. 2A).

To investigate the retrotransposition activity of SVA relative to processed pseudogene formation, we scaled up our assay from six-well plates to T-75 flasks (see Methods and Materials). We co-transfected cells with pcDNA.L1-RP and the following SVA constructs: SVA.10 *mneoI*, SVA.10B *mneoI*, SVA.2 *mneoI*. Additionally, the progenitor to the *SPTA1* (α -spectrin) insertion (5), an SVA_E representing another 'canonical' SVA element, referred to as SRE1, was tested with (SVA.SRE1 *mneoI*) and without (99 SVA.SRE1

Table 1. Retrotransposition activity of marked SVAs in HeLa HA cells

Passenger	pcDNA.L1-RP		Activity	No driver	
	<i>n</i>	Number of G418 ^R		<i>n</i>	Number of G418 ^R
SVA.10 <i>mneoI</i>	3	124.7 ± 17.8	54.2	2	1.0 ± 1.0
SVA.10B <i>mneoI</i>	3	7.3 ± 1.9	3.2	2	0.0 ± 0.0
SVA.2 <i>mneoI</i>	3	14.7 ± 3.5	6.4	2	0.5 ± 0.5
SVA.SRE1 <i>mneoI</i>	2	2.5 ± 1.5	1.1	2	0.0 ± 0.0
99 SVA.SRE1 <i>mneoI</i>	2	7.0 ± 0.0	3.0	2	0.0 ± 0.0
ORF1 <i>mneoI</i> -AA	3	11.3 ± 2.0	4.9	2	0.0 ± 0.0
EGFP <i>mneoI</i>	3	2.3 ± 0.7	1.0	2	0.0 ± 0.0

Transfection of approximately 2×10^6 HeLa HA cells was carried out in T-75 flasks with 8 µg of the driver plasmid DNA and 4 µg of the passenger plasmid DNA. In the column labeled 'No driver', only 4 µg of the passenger plasmid DNA was transfected. Following G418^R selection, flasks were stained and colonies counted. The data are presented as the mean number of G418^R colonies across replicates ($n \pm$ SEM). Activity is the number of G418^R for each passenger divided by the number of EGFP *mneoI* G418^R.

mneoI) an exogenous promoter. We also co-transfected the following control plasmids with pcDNA.L1-RP: (i) ORF1 *mneoI*-AA (31), a construct containing the ORF1 coding sequence with two point mutations (R261A/R262A) marked with *mneoI*, and (ii) a marked pseudogene, EGFP *mneoI*, the coding sequence of EGFP along with *mneoI* in pCEP4. As a negative control, all passenger constructs were transfected alone (no driver). We normalized the number of G418^R foci for each passenger to the number of G418^R foci produced by the pseudogene EGFP *mneoI*. The results are presented in Table 1 (Fig. 3B).

Consistent with the results of performing transfections in six-well plates, SVA.10 *mneoI* produced the most foci (mean = 124.7 ± 17.8) per T-75 flask and SVA.2 *mneoI* produced the second greatest number of foci (mean = 14.7 ± 3.5). These engineered SVAs produce foci 1–54 times more often than a marked pseudogene (Table 1). Notably, steady-state RNA levels differ across these constructs (Fig. 2A) and correlate with the retrotransposition activity for SVA.10 *mneoI* and SVA.10B *mneoI*.

The role of L1 proteins in SVA *trans*-mobilization

Both L1 proteins are required in *cis* to mobilize their own RNA (24). Likewise, processed pseudogene formation requires a functional ORF1p (23,26). However, *Alu* elements only require L1 ORF2p, although supplementation with L1 ORF1p may enhance *Alu* retrotransposition (69). To determine the role of L1 ORF2 in SVA *trans*-mobilization, our SVA constructs were co-transfected with an L1 containing a point mutation (D702Y) in the reverse transcriptase domain, known to abolish RT activity (70) (Fig. 2D). Consistent with a requirement for L1 ORF2p RT activity, few to no colonies were observed for engineered SVAs, ORF1 *mneoI* and *Alu neo*^{Tet} when co-transfected with L1-RP (D702Y) (Fig. 2D). These data are consistent with SVA *trans*-mobilization through an RNA intermediate.

Next, we tested whether the L1 RNA-binding protein ORF1p is required for SVA retrotransposition (Fig. 2E and

F). Here, we co-transfected either SVA.10 *mneoI* or SVA.2 *mneoI* with a construct containing the 5' UTR and ORF2 coding sequence of L1.3 (65,66,71) cloned into pcDNA6 (pcDNA.ORF2). Consistent with previous reports, *Alu* mobilization is enhanced when transfected with an ORF2-only construct rather than a full-length L1 (Fig. 2E) (25). Few-to-no colonies were observed when SVA.10 *mneoI* was co-transfected with pcDNA.ORF2 (0.5 ± 0.22). However, retrotransposition of SVA.2 *mneoI* co-transfected with pcDNA.ORF2 produces slightly more foci (5 ± 0.4) than transfection with full-length L1 drivers. To further investigate the potential ORF1p requirement of SVA.10 *mneoI*, co-transfection with ORF2 in a replicating plasmid, pCEP.ORF2, was carried out (Fig. 2F). Similar to what was observed with pcDNA.ORF2, few-to-no colonies (0.5 ± 0.22) were observed in this assay, despite quite robust *Alu* mobilization (96.25 ± 16.11) (Fig. 2F).

ORF1p is a multi-domain protein that contains coiled-coiled, RRM and C-terminal domains (72,73). To further investigate the role of ORF1p in SVA retrotransposition, we carried out experiments with a driver, pcDNA.L1-RP_{N157A/R159G}, containing the double mutation, N157A/R159G (74), in the RRM domain of ORF1p. This mutation has been shown to abolish engineered L1 retrotransposition in *cis*, to affect L1 RNP formation and to disrupt both the formation of ORF1p cytoplasmic foci (74) and L1 cytoplasmic foci formation containing ORF2p (75). As a positive control for *trans*-mobilization, pcDNA.L1-RP_{N157A/R159G} was transfected with ORF1 *mneoI* (23), as ORF1 *mneoI* does not require a functional ORF1p in *trans* (31) for mobilization. ORF1 *mneoI* transfected with pcDNA.L1-RP_{N157A/R159G} results in slightly fewer foci (40.33 ± 2.33) than ORF1 *mneoI* driven with pcDNA L1-RP (51.67 ± 13.48) (Fig. 2G). In contrast, transfections of either SVA.10 *mneoI* or SVA.2 *mneoI* with pcDNA.L1-RP_{N157A/R159G} resulted in almost no colony formation (0 ± 0 and 0.2 ± 0.2) (Fig. 2G). Therefore, these data suggest that SVA.2 retrotransposition is ORF1p independent, whereas SVA.10 retrotransposition is ORF1p dependent in HeLa HA cells. However, a driver L1 containing the double mutation, N157A/R159G, reduces SVA mobilization to background levels.

Engineered SVAs retrotranspose in multiple cell lines

Our understanding of L1 biology has benefited from analysis across various cell types or cell lines of varying origin (reviewed in 34). Likewise, the EGFP retrotransposition indicator cassette (76) has been useful in reducing the amount of time it takes to carry out these assays and in interrogation of phenomena intractable to the *neo* assay (33). Therefore, we re-engineered SVA.10 and SVA.2 with the EGFP retrotransposition indicator cassette. Likewise, we tested a modified SVA.10 EGFP construct in which we removed the 3' transduction and restored the 3' end of the SINE-R to make SVA.10R EGFP. Similar to the *mneoI* cassette, the EGFP cassette remains non-functional until a round of transcription is followed by integration (76).

To test our new constructs, we transfected our EGFP-marked SVAs into HeLa HA cells, as we have demonstrated these cells are permissive for SVA retrotransposition. As a

robust positive control for retrotransposition, we transfected 99 RPS EGFP Pur (76), a construct containing the highly active L1-RP (64) driven by its own promoter. To maintain plasmid DNA to transfection reagent ratios similar to that of the SVA co-transfections, the L1 driver, pcDNA.L1-RP (FL-L1), was co-transfected with 99 RPS EGFP Pur. As a positive control for *trans*-mobilization, JM111 EGFP Pur (76) and a driver L1 were also co-transfected. JM111 *mneoI* has been reported to be mobilized *in trans* at detectable levels in six-well plates by L1 driver constructs (23). SVA retrotransposition, as indicated by EGFP-positive cells, was detectable as early as day 2 under the microscope.

In these assays, we opted to select for the plasmid marked with the EGFP cassette with puromycin. Five days after transfection, cells were counted by flow cytometry to determine the number of EGFP-positive cells. Routinely, at least ~100 000 transfected cells were counted to obtain reasonable sample size. Retrotransposition frequencies were calculated as the number of EGFP-positive cells per number of transfected cells (see Materials and Methods for more details). All samples were gated on cells co-transfected with SVA.10 EGFP and the pcDNA.L1-RP (D702Y) mutant, as this represents background fluorescence or any effect of endogenous RT activity. Both SVA constructs, SVA.10 EGFP and SVA.2 EGFP, were transfected with an ORF1 driver, pcDNA.ORF1, or an ORF2 driver, pcDNA.ORF2, to confirm our data from the *neo* assay regarding SVA L1 protein requirements. To examine whether L1 proteins may mobilize SVAs when supplied jointly in *trans*, and because a previous report suggests that retrotransposition of *Alu* by ORF2 alone is enhanced when ORF1 is supplemented (69), SVA.10 EGFP or SVA.2 EGFP was co-transfected with ORF1 and ORF2 on separate plasmids (pcDNA.ORF1 and pcDNA.ORF2, respectively). To control for the reduction in plasmid containing ORF2 sequence when ORF1 and ORF2 sequences are on different plasmids, additional transfections were carried out in which the amount of L1 driver plasmid was reduced by a factor of 2 (FL-L1/2). All transfections were carried out in triplicate unless indicated otherwise and are presented as the mean %EGFP-positive cells \pm 1 standard deviation (Fig. 4).

In the HeLa HA cell experiment, EGFP-positive cells derived from SVA.10 EGFP were 0.06% of transfected cells, corresponding to 22% of 99 RPS EGFP Pur activity ($0.27\% \pm 0.04$). Although some SVA.2 EGFP and JM111 retrotransposition events were seen under an inverted microscope, EGFP-positive events were not detectable above background by flow cytometry (Fig. 4B). As expected, SVA.10 EGFP and SVA.2 EGFP co-transfected with pcDNA.ORF1 produced no events. SVA.10 EGFP and SVA.2 EGFP transfections with pcDNA.ORF2 produced detectable events, although very rarely (Fig. 4B). When SVA.10 EGFP and SVA.2 EGFP were transfected with the ORF1 and ORF2 on different plasmids (pcDNA.ORF1 + pcDNA.ORF2), a noticeable increase in the %EGFP positive cells was observed (Fig. 4B). SVA.10 EGFP is active ($0.02\% \pm 0.01$) when co-transfected with an equal amount of ORF2 containing plasmid DNA, but increases to $0.08\% \pm 0.14$ with ORF1 and ORF2 on separate plasmids. SVA.2 EGFP increases from background levels to $0.20\% \pm$

0.02 when co-transfected with ORF1 and ORF2 on separate plasmids. Thus, our SVA EGFP assay was validated and we decided to explore SVA retrotransposition in other cell lines.

Engineered L1s retrotranspose at high levels in the human embryonic kidney (HEK) cell line, 293T (77), and in the osteosarcoma cell line, 143B (78). In addition to these cell lines, we also transfected U2OS cells, another osteosarcoma cell line, with our three SVA EGFP constructs. The same experiment carried out for HeLa HA cells was replicated in 293T cells, although we only assayed SVA mobilization by full-length L1 in 143B and U2OS cells. Similar to HeLa HA cells, SVA retrotransposition was observed as early as day 2 in 293T cells and day 3 in U2OS cells (Fig. 4A). Flow cytometry data for the 293T and U2OS cells are presented in Figure 4C and D, respectively. In contrast, SVA retrotransposition in 143B cells was low, with only SVA.10 EGFP events detectable by flow cytometry (Fig. 4E) while the other passenger constructs were not above background.

In 293T cells, both JM111 and ORF2-alone *trans*-mobilization of SVA.10 EGFP and SVA.2 EGFP was increased relative to HeLa HA cells (Fig. 4B). In U2OS cells, 99RPS EGFP Pur activity was reduced relative to HeLa HA or 293T cells. The SVA EGFP constructs exhibit the highest percentage of EGFP cells in U2OS cells, up to 0.1% of transfected cells for SVA.10 EGFP. It is noteworthy that the SVA activity is comparable with the L1 activity in this cell line. These SVA EGFP assays show that multiple cell types are permissive to engineered SVA retrotransposition, support our observations from the *neo* assay regarding ORF1p independence of SVA.2, and identify at least one cell line where SVA and L1 retrotransposition activity is similar.

SVA insertions display hallmarks of L1-mediated retrotransposition

To confirm that colony formation resulted from authentic retrotransposition events, SVA.10 *mneoI*, SVA.2 *mneoI*, SVA.10 *mneoI* Δ 3TR, SVA.SRE1 *mneoI* and 99 SVA.SRE1 *mneoI* events were clonally expanded and genomic DNA was extracted from clones. First, we carried out PCR with primers spanning the intron of *mneoI* (Fig. 5A and data not shown). Consistent with engineered SVAs being mobilized through an RNA intermediate, amplicons representing a spliced *mneoI* PCR product were observed in genomic DNA isolated from individual clonal lines. Sanger sequencing confirmed that the lower bands represented spliced *mneoI* PCR products (data not shown).

To map the location of engineered SVA insertions and characterize the breakpoints, we carried out inverse PCR (iPCR). Genomic DNA from independent foci was digested with restriction enzymes that cut towards the 3' end of the SINE-R or within the *mneoI* cassette. This approach should (i) minimize bias in insertion size of SVA inserts and (ii) circumvent PCR amplification problems associated with the SVA GC-rich VNTRs. However, this approach only allows recovery of the 3' breakpoints of SVA inserts.

We recovered the genomic location of 15 SVA insertions from clonal cell lines (Table 2) (see Material and Methods). Ten out of 15 (66%) engineered SVA insertions are located in genes, including one in the 3' UTR of a gene (clone 10)




Figure 4. Engineered SVAs retrotranspose in multiple cell lines. (A) SVA.2 EGFP-positive foci at day 3 in U2OS cells are shown. SVAs are marked (*x*-axis) with the EGFP retrotransposition indicator cassette (76) and co-transfected with L1 drivers in HeLa HA (B), HEK 293T(C), U2OS (D) and 143B cells. All transfections were carried out in six-well plates (see Methods and Materials). Five days after transfection, cells were subjected to flow cytometry. Retrotransposition frequency was calculated as the number of events (EGFP-positive cells) relative to the number of cells transfected (*y*-axis) with the designated passenger plasmids (B–E). Events were gated on cells co-transfected with SVA.10 EGFP and pcDNA.L1-RP (D702Y). 99 RPS, 99 RPS EGFP Pur; JM111, JM111 RPS EGFP Pur; FL-L1, pcDNA.L1-RP (FL = L1/2 refers to a reduction in the amount of pcDNA.L1-RP transfected); ORF1, pcDNA.ORF1; ORF2, pcDNA.ORF2; ORF1/ORF2, co-transfection with pcDNA.ORF1 and pcDNA.ORF2 on separate plasmids. All transfections were performed in triplicate, except SVA.10R EGFP Δ3TR and SVA.10 EGFP/ORF1/ORF2 in HeLa HA cells. Where included, the mean %EGFP-positive cells is given. Error bars represent 1 standard deviation.

and another breakpoint located directly 5' of the AG splice acceptor of an exon (clone 7). Six out of 10 (60%) of the insertions in annotated genes are on the coding strand. RNA from the SVA.10 *mneoI* construct has the capability of polyadenylating at a polyA site in the 3' transduction (59,60) or downstream at the SV40 polyA signal located in the CEP vector, as commonly observed for engineered L1s (24). Four out of five recovered SVA.10 *mneoI* insertions terminated

downstream of the cloned 3' transduction at the SV40 polyA signal. Therefore, these five 3' ends represent SVAs that contain 3' transductions.

Of the nine insertions for which we obtained both the 5' and 3' breakpoints (Fig. 5 and Table 2), TSDs were observed flanking the insertions (range 12–265 nt, mean excluding the 265 nt TSD = 15.3) (Table 2), insertions occurred at sequences resembling the L1 endonuclease consensus




Figure 5. Engineered SVA insertions recovered from genomic DNA resemble SVA genomic insertions and display hallmarks of L1-mediated retrotransposition. Intron-spanning PCR was carried out on genomic DNA isolated from clonal cell lines derived from individual foci produced by different SVAs (A). Unspliced and spliced *mneI* bands are indicated by black horizontal arrows. The 5' and 3' ends for SVA.10 *mneI* insertions recovered from individual foci (B–F). The genomic coordinates relative to the reference genome assembly (hg19/NCBI37) for each insertion are shown (right corner). The insertion-site nucleotide sequence consisting of the target-site duplication (bold letters), the L1 endonuclease cleavage site of the bottom strand (black vertical arrow) relative to the L1 endonuclease consensus cleavage site (5'-TTTT/a-3') and 10 nucleotides 5' and 3' of the TSD are displayed. Each SVA insertion, including TSDs (black arrows), polyA signal and length of polyA tail, is diagrammed with individual domains annotated as described in Fig. 1B.

Table 2. SVA insertions recovered from HeLa HA genomic DNA

Clone	SVA construct	Genomic location	Gene	Strand	Length (kb) (domain) ^a	TSD (length)	L1 EN site TTTT/a	PolyA length ^b
1	SVA.10 <i>mneoI</i>	CH7p22.1	<i>RNF216</i>	Coding	~5.4 (full-length)	CAAATTACTGAAGG (17)	TTTG/a	~42
2	SVA.10 <i>mneoI</i>	CH17p11.2	<i>TOM1L2</i>	Coding	~5.6 (full-length)	AAGAAAAGGTCATC (14)	TCTT/g	~90
3	SVA.10 <i>mneoI</i>	CH17p11.2	<i>MPRIP</i>	Coding	~5.5 (full-length)	AGAAAAATCTTTTCTT (16)	TTCT/g	~60
4	SVA.10 <i>mneoI</i>	CH1p36.13	—	n/a	—	—	—	~81
5	SVA.10 <i>mneoI</i>	CH4q31.1	—	n/a	~4.5 (<i>MAST2</i>)	AAAAAAATAT... (265)	TTTT/a	~63
6	SVA.10 <i>mneoI</i> Δ3tr	CH5q13.2	<i>SMA4/SMN2</i>	Coding	~5.0 (full-length)	AAAGTCTGAAAA (12)	CTTT/a	~43
7	SVA.10 <i>mneoI</i> Δ3tr	CH19q13.2	<i>MED29</i>	Coding	—	—	—	~67
8	SVA.2 <i>mneoI</i>	CH2q32.1 ^c	—	n/a	—	—	—	~39
9	SVA.2 <i>mneoI</i>	CH2q32.1 ^c	—	n/a	—	—	—	~99
10	99 SVA.SRE1 <i>mneoI</i>	CH8p21.3	<i>AL833246/LOXL2</i>	Coding ^d	~1.5 (SINE-R)	AAAGAAACGGAGGCTCTTGAA (21)	CTTT/c	~31
11	99 SVA.SRE1 <i>mneoI</i> (VNTR)	CH20q13.32	AK091704/	—	AK054637	Non-Coding	~2.5	~70
12	99 SVA.SRE1 <i>mneoI</i>	CH22q11.21	<i>PI4KA</i>	Non-coding	~2.2 (VNTR)	AAATAAAGTTCCTG (14)	TTTT/a	~44
13	99 SVA.SRE1 <i>mneoI</i>	CH1q25.3	<i>C1orf14</i>	Non-coding	~2.9 (VNTR)	AAAATCGAGTAGTATG (16)	ATTT/a	~29
14	99 SVA.SRE1 <i>mneoI</i>	CH14q24.2	—	n/a	—	—	—	~111
Mean ^e	—	—	—	—	3.9	43.0 (15.3)	—	62.1

Recovered SVA insertions are listed by clone number (column 1), the SVA construct (column 2) from which the foci was produced, the genomic location of the 3' junction (column 3), whether it was in a gene (column 4) and orientation relative to the coding strand (column 5). Column 6 lists the length of the total retrotransposed sequence, therefore it includes the length of the *mneoI* retrotransposition indicator cassette (~1.1 kb) and the domain in which the insertion 5' truncates. Column 7 lists the TSD length in nucleotides. Column 8 lists the L1 endonuclease (EN) cleavage site on the bottom strand, with the consensus cleavage EN site listed in parentheses. Column 9 lists the approximate polyA length given in nucleotides.

^aThe length of the SVA constructs (kb) including spliced *mneoI* from the 5' end of the element to the SV40 polyA signal in pCep: SVA.10 *mneoI* = 5.5; SVA.10 *mneoI*Δ3tr = 4.9; SVA.2 *mneoI* = 3.5; 99 SVA.SRE1 *mneoI* = 4.0 from the CCCTCT hexamer (4.7 including the 5' flank).

^bSVA.10 *mneoI* contains an additional polyA signals in the 3' transduction. Despite this, all engineered SVA insertions except clone 1 terminated at the SV40 polyA signal.

^cThese SVAs are different insertions. Clone 1 inserted into an L1MA3,chr2:187430675, whereas clone 2 inserted upstream at chr2:185062822.

^dThis locus consists of two genes, *AL833246* on the positive strand and *LOXL2* on the bottom strand. The insertion breakpoint is located in sequence that is annotated as the 3' UTR for *AL833246*.

^eThe mean length across engineered SVA insertions where the 5' end was characterized, mean length of TSDs with and without the 265 nt TSD and polyA tail length are shown. The genomic coordinates and gene annotations are according to hg19 (<http://genome.ucsc.edu>).

cleavage site (5'-TTTT/A-3') (Table 2 and Fig. 6A) (22,29,36,79–81), and the insertions contained polyA tails of variable length (range 29–111 nt, mean = 59.2 nt).

Four out of five SVA.10 *mneoI*/SVA.10 *mneoI*Δ3TR insertions were full-length. The first nucleotide, that is not part of the TSD for these insertions, was located +2 to +5 relative to the transcription start site of the CMV promoter (82) (Fig. 6B), 12–16 nt 5' of the cloned SVA fragment in pCEP4. One of these insertions, clone 3, contains a non-templated G (Fig. 6B). Thus, these insertions contain short 5' transductions. The average length of the SVA.10 *mneoI*/SVA.10 *mneoI*Δ3TR insertions was ~5.2 kb with the *mneoI* cassette and ~4.0 kb without the cassette. In contrast, all four 99 SVA.SRE1 *mneoI* insertions were 5' truncated, three within the VNTR and one in the SINE-R domain (Table 2). The mean length of the 99 SVA.SRE1 *mneoI* insertions was ~2.3 kb with the *mneoI* cassette and ~1.1 kb without the cassette. The combined mean length of the nine insertions, where 5' and 3' breakpoints were obtained, was 3.9 kb with the cassette and 2.7 kb without the cassette.

DISCUSSION

SVA is mobilized by human L1s in *trans*

Here, we provide the first experimental evidence for L1-mediated retrotransposition of SVA elements in cultured cells. SVA elements display all the hallmarks of LINE-1 mobilization; however, the establishment of an SVA retrotransposition assay has been delayed, at least in our hands, due to false-positive insertions and the lack of an appropriate progenitor element. Source elements to L1 disease-causing insertions have proven useful—robust models for L1 retrotransposition; however, this has not been the case for SVA insertions. In this study, we opted to use elements known to be relatively active since the human–chimpanzee divergence, one element from the recently described youngest human-specific SVA subfamily, SVA.10, and one element representing the ‘canonical’ SVA, SVA.2.

Consistent with the multiple daughter loci produced from the SVA.10 or SVA.2, both elements are rather active in multiple cell types. In some cell types, our SVA constructs are not




Figure 6. Engineered SVA insertions resemble SVA genomic insertions. **(A)** A consensus sequence, generated using WebLogo (86), for engineered SVAs insertion sites resembles the L1 endonuclease consensus cleavage site (5'-TTTT/a-3') (79–81) (Table 2). **(B)** An alignment of four SVA.10 *mneoI* insertions, containing 5' transductions, relative to the SVA.10 *mneoI* plasmid sequence. The 3' end of the CMV promoter in CEP labeled along with the known CMV transcriptional start site (black bent arrow). Note that the first base of each insertion is within 5 nt of the CMV transcriptional start site. For insertion 3, a non-templated G at the 5' breakpoint is displayed as (G).

as actively *trans*-mobilized as JM111 EGFP. However, it is interesting that, in U2OS cells, SVA retrotransposition rivals that of one of the most active human L1s, L1 RP. It is possible that SVAs may mobilize sooner in U2OS cells than human L1, and that over a longer time period, engineered L1 retrotransposition would far surpass that of engineered SVAs.

SVA elements are thought to be 'hot' because numerous recent insertions are associated with Mendelian disease (57,83). SVA activity in our HeLa HA cell culture assays ranges from ~1 to 54 times that of a pseudogene. Excluding SVA.10 *mneoI* which contains a few mutations introduced by cloning, SVA activity ranges from approximately one to six times the activity of a pseudogene. It is surprising to us, that SVA.10 and SVA.2 exhibit an ~8-fold difference in retrotransposition activity (Fig. 2A and Table 1) in HeLa HA cells, whereas in U2OS cells they are not significantly different in activity. Furthermore, it is possible that either the appropriate cell line or precise time *in vivo* is needed not only for increased SVA activity but also for intrinsic SVA promoter activity to occur. An alternative and equally possible explanation for the modest SVA activity is that SVA elements are not very active overall, and that an unknown ascertainment bias accounts for SVA disease-associated insertions. However, it bears mentioning that engineered L1s are silenced following insertion by deacetylation of the local chromatin (33), and SVA insertions may also be silenced. Along these lines, SVA was originally identified by one laboratory (54) in a screen for densely CpG-methylated loci.

SVA L1 protein requirement

SVA mobilization through an RNA intermediate is supported by our retrotransposition reporter assays along with engineered SVA insertions containing spliced introns and polyA tails. Consistent with these observations, use of an L1 driver containing a point mutation in the RT domain reduces *trans*-mobilization of SVA and control constructs to background levels. Previous studies of *trans*-mobilization determined that ORF1p is dispensable for *Alu* retrotransposition (25) although it is required for pseudogene formation (23,26). Data from our *neo* assay (Fig. 2E and F) suggest a strict ORF1p requirement for SVA.10 mobilization and little-to-no ORF1p requirement for SVA.2 in HeLa HA cells. Despite an increase in ORF2-alone mobility in EGFP assays,

SVA.10 is still mobilized more effectively by the full-length L1. However, it is evident in 293T cells that SVA.2 EGFP is indeed mobilized more efficiently by ORF2 alone relative to full-length L1. Of particular interest is the 10–20-fold increase in SVA EGFP-positive cells when ORF1 and ORF2 are transfected jointly on separate plasmids. It has been reported that *Alu* retrotransposition is enhanced up to 5-fold when *Alu* and ORF2-alone transfections are supplemented with ORF1 (69). Why ORF1 and ORF2 delivered on separate plasmids are more active as SVA drivers than full-length L1 is unknown. One possibility is that more ORF2p is synthesized from the monocistronic CMV-driven ORF2-alone construct (75) than ORF2p produced by a full-length L1. Nonetheless, this observation may prove useful for interrogating SVA biology.

The differential ORF1p requirement for SVA.10 and SVA.2 is surprising. This difference may be related to RNA length, as a full-length spliced SVA.10 *mneoI* RNA is ~5.5 kb compared with ~3.5 kb for a full-length spliced SVA.2 *mneoI* RNA, or perhaps more specifically the length of the 3' transduction. In addition to size differences, SVA.10 and SVA.2 are quite different at the DNA sequence level, with SVA.10 containing multiple 5' and 3' transductions and lacking the CCCTCT hexamer and most of the *Alu*-like domain.

Engineered SVA insertions

Our recovered SVA insertions display features similar to genomic SVAs: 5' transductions, 3' transductions, TSDs, polyA tails and insertion at L1 endonuclease consensus cleavage sites (Table 2, Figs 5 and 6). Four out of five SVA.10 insertions begin at the CMV promoter transcriptional start site, supporting the hypothesis that these elements lack strong promoter sequences and the observation that the majority of SVAs (~63%) in the human genome reference sequence are full-length (60). In contrast, the 99 SVA.SRE1 *mneoI* insertions are produced from a vector that contains no CMV promoter. Alternatively, it is possible that a cryptic promoter exists on the plasmid backbone or within the ~700 bp of 5' flank cloned with this element. Additionally, it is possible that the SRE1 insertions do not represent 5' truncations at all, and that SVA transcription initiated within the VNTR as numerous transcription start sites exist throughout the SVA

sequence. The locations of the SVA inserts suggest they readily insert into genes (66.6%). If the phenomenon of preferred intragenic insertion that we have seen in our cell culture assays is representative of new SVA insertions in humans, SVAs may indeed contribute to individual variation in gene expression either by mediating alternative splicing or by increasing DNA methylation at a locus. Six out of 10 of the engineered SVA insertions are on the coding strands of genes. This differs from the observation that, in the human reference genome, only 20% of intragenic SVAs are on the coding strand (59).

What is particularly striking is that four out of five SVA.10 *mneoI* insertions (80%) and four out of nine (44%) of the total recovered insertions are full-length. While this may represent some unknown technical bias, the iPCR approach should limit bias as the restriction enzymes used cut towards the 3' end of the engineered element. The longer insertions differ greatly from reports for engineered L1 insertions in which the L1 is driven by a heterologous promoter and only ~5% of the insertions are full-length (22,35,36). Here, it is possible that a size ascertainment bias may have been introduced, as some of these studies relied upon rescue cassette procedures which likely favor easier ligation and smaller insertions. However, a study characterizing transgenic human L1 insertions in mice, where the insertions were recovered by a ligation-independent method, TAIL-PCR, reported that 3/33 (9%) insertions were full-length (40). More recently, another transgenic study that characterized human L1 insertions in the mouse and rat, where the L1 was driven by its own promoter, reported that four out of eight were full-length (38).

The full-length SVA insertions here and in the genome are a testament to the resilience of the L1 RT. Moreover, the ability to reverse-transcribe such a repetitive GC-rich template, as occurs in SVA, argues against a model in which L1 5' truncations are the consequence of reduced L1 RT processivity and favors the hypothesis that some as-yet unidentified factor is responsible for truncations.

This study provides the first comprehensive analysis of SVA molecular biology to date. Here we extend our current understanding not only of SVA biology but also of L1-mediated retrotransposition. Our assay will not only be useful for comparative studies but may also provide insight into this young, mysterious element.

MATERIALS AND METHODS

Oligonucleotide sequences used in this study are available upon request.

Recombinant DNA plasmids

SVA.10 *mneoI*: This construct contains a *KpnI*-*AgeI* 3.5 kb fragment consisting of the *MAST2*-SVA (57,60) from the CH10 locus (10q24.2) and its 5' transductions (including 5'*Alu*), the *mneoI* retrotransposition indicator cassette (24,62) and a 0.5 kb *SbfI*-*NotI* fragment consisting of the 3' transduction from the *ABCC2* locus, containing the last 23 bp of the SINE-R, SVA polyA signal and polyA tail, the 3' *Alu* and the 160 bp transduction, all cloned into

pCEP-Pur, a modified pCEP4 (Invitrogen) vector containing the puromycin resistance gene (76).

SVA.10 *mneoI* Δ3TR: This construct contains a *KpnI*-*AgeI* 3.5 kb fragment consisting of the *MAST2*-SVA (57,60) from the CH10 locus (10q24.2) and its 5' transductions (including 5' *Alu*), and the *mneoI* retrotransposition indicator cassette (24,62) cloned into pCEP4-Pur.

pcDNA.L1-RP: L1-RPS was liberated from pJCC5(L1_{RP}) (76) as a 6 kb *NotI*-*ApaI* fragment and swapped into the *NotI*-*ApaI* sites of pcDNA6/*myc*-hisB (Invitrogen).

pcDNA.L1-RP(D702Y): This construct was generated by site-directed mutagenesis of pcDNA.L1-RP.

pcDNA6.ORF2: The L1.3 5'-UTR-ORF2 was liberated from pCEP 5'-UTR-ORF2 no *neo* (71) as a 4.8 kb fragment and swapped into pcDNA.L1-RP at *NotI*-*AleI*.

pCEP.ORF2: Referred to as pCEP 5' UTR ORF2 no *neo*, pCEP.ORF2 has been previously described (71).

***Alu neo*^{Tet}:** This construct has been previously described (25).

SVA.2 *mneoI*: The SVA locus on CH2 was isolated from genomic DNA by PCR and cloned into pBluescript as a 3.9 kb *KpnI*-*HindIII* fragment to make pBS SVA.2. The SVA.2 was liberated as a 2 kb *KpnI*-*PpuI* fragment and swapped into the *KpnI*-*PpuI* sites in pBS SINE-R.10 *mneoI*, a vector containing the complete SINE-R, derived from SVA.10, to make pBS SVA.2 *mneoI*. SVA.2 with the *mneoI* retrotransposition indicator cassette was swapped as a 4.2 kb *KpnI*-*NotI* fragment into pCEP-Pur *KpnI*-*NotI* sites to make SVA.2 *mneoI*.

SVA.10.B *mneoI*: SVA.10 *mneoI* with the 3' transduction, consisting of the 3' transduction from the *ABCC2* locus, containing the last 23 bp of the SINE-R, SVA polyA signal and polyA tail, the 3' *Alu* and the 160 bp transduction, was recloned from BAC DNA as a 0.5 kb *SbfI*-*NotI* fragment.

SVA.10 *neo*^{Tet}: This construct is the same as SVA.10 *mneoI* except it contains the *neo*^{Tet} retrotransposition indicator cassette (25) cloned in as an *AgeI*-*SbfI* fragment.

ORF1 *mneoI*: This construct has been described previously (23).

ORF1 *mneoI*-AA: This construct has been described previously (31).

pcDNA.L1.3: L1.3: This construct was liberated from JM101/L1.3 (66) as a 6 kb *NotI*-*AleI* fragment and swapped into pcDNA.L1-RP at *NotI*-*AleI* sites.

pcDNA.L1-RP_{N157A/R159G}: This construct was generated by swapping a *NotI*-*BstEII* fragment from pEGFP-N3 L1-RP_{N157A/R159G} (74) and swapped into pcDNA.L1-RP.

pcDNA.ORF1-RP: This construct contains the 5' UTR and ORF1 from L1-RP cloned into *NotI*-*AgeI* of pcDNA6 as a 2 kb *NotI*-*XmaI* fragment.

pcDNA.L1-RPΔΔ: This construct contains a 5 kb L1-RP sequence lacking the L1 5' UTR cloned into a modified pcDNA6 vector lacking the CMV promoter.

SVA.SRE1 *mneoI*: This construct contains the source element (SVA Retrotransposable Element) to the *SPTA1* insertion (5). This element is marked with the *mneoI* retrotransposition indicator cassette (24,62) in pCEP4 and contains ~700 bp 5' flanking sequence.

99 SVA.SRE1 *mneoI*: This construct is the same as SVA.SRE-1 *mneoI* but is cloned into a modified pCEP vector (24) lacking the CMV promoter.

EGFP *mneoI*: This construct consists of the EGFP coding sequence from pEGFP-N1 (CLONTECH) cloned into pCEP4 and marked with the *mneoI* retrotransposition indicator cassette (24,62).

99 RPS EGFP Pur: This construct has been described previously (76).

99 RPS JM111 EGFP Pur: This construct has been described previously (76).

SVA.10 EGFP: This construct is similar to SVA.10 *mneoI*, except it contains the ~2.5 kb EGFP retrotransposition indicator cassette (76) cloned in as an *AgeI*–*SbfI* fragment.

SVA.2 EGFP: The EGFP retrotransposition indicator cassette was swapped into pBS SVA.2 *mneoI* as a 2.5 kb *SallI*–*NotI* fragment to make pBS SVA.2 EGFP. pBS SVA.2 EGFP was liberated as a 4.5 kb *KpnI*–*NotI* and ligated into *KpnI*–*NotI* sites in pCEP-Pur.

SVA.10R EGFP Δ 3TR: SVA.10 was liberated as a 3.5 kb *KpnI*–*PpuMI* fragment from pBS SVA.10 *mneoI* and swapped into pBS SVA.2 EGFP at *KpnI*–*PpuMI* sites to make pBS SVA.10R EGFP Δ 3TR. pBS SVA.10R EGFP Δ 3TR was liberated as a 6.2 kb *KpnI*–*NotI* and ligated into *KpnI*–*NotI* sites in pCEP-Pur.

DNA preparation

Plasmid DNA was prepped using the QIAGEN MaxiPrep Kit (QIAGEN). Genomic DNA was isolated using the DNA Mini Kit (QIAGEN).

Cell culture

HeLa HA, HEK 293T, U2OS and 143B cells were incubated at 37°C with 5% CO₂ and 100% humidity in DMEM (Gibco) supplemented with 10% FBS (Hyclone), 1% Penn-Strep (Gibco) and 1% GlutaMax (Gibco).

neo Trans-mobilization assays

Transient retrotransposition assays (84) were carried out similarly to those previously reported for *Alu* (67,71), with slight modifications. For assays in six-well and T75 flasks, we seeded out ~2 × 10⁵ or ~2 × 10⁶ HeLa HA cells per well/flask. The following day, 0.5 µg of the passenger and 1.5 µg of the driver plasmid DNA or 4 µg of the passenger and 8 µg of the driver plasmid DNA for T75 flasks were co-transfected using 6 µl Fugene (Roche) according to the manufacturer's instructions. Seventy-two hours after transfection, G418 was added to the cells. Cells were re-fed routinely with media containing G418. After G418 selection, approximately 14 days, cells were washed, fixed and stained with giemsa.

SVA.10 *mneoI* retrotransposition frequency was calculated as the number of G418^R foci per transfected cell. Transfection efficiency was determined by co-transfecting 0.5 µg of N1-EGFP (CLONTECH) in addition to 0.5 µg of SVA.10 *mneoI* and 1.5 µg of the driver plasmid using 6 µl Fugene (Roche) into HeLa HA cells in six-well plates. One day after transfection, EGFP-expressing cells were counted using an Accuri C6 flow cytometer. The mean percentage of EGFP-expressing cells from three replicates was calculated.

Northern blot analysis of SVA RNA in HeLa HA cells

HeLa HA cells were seeded in a 10 cm plate at a density to achieve 50% confluency at the time of transfection. Fugene 6 was used to transfect 2 µg of the driver (pcDNA.L1-RP) plasmid DNA and 4 µg of the passenger plasmid DNA into HeLa HA cells. Total RNA was isolated after 48 h using the RNeasy Mini Kit (QIAGEN). RNA was mixed with NorthernMax-Gly Sample Loading Dye (Ambion) at a 1:2 RNA:dye ratio, incubated at 55°C for 1 h, chilled on ice for 5 min before loading. Ten micrograms of total RNA was separated on a 1% denatured agarose gel. The RNA was transferred to a nylon membrane, UV-crosslinked and pre-hybridized at 68°C for 1 h, followed by overnight hybridization at 68°C with a *neo* sense riboprobe (300 bases), lacking the intron, labeled with digoxigenin (DIG)-11-UTP. The next day, the membrane was washed, immunodetected with anti-DIG-AP Fab fragments (Roche), visualized with the chemiluminescence substrate CDP-star (Roche) and exposed.

EGFP retrotransposition assays

Approximately 2 × 10⁵ HeLa HA, 293T, U2OS or 143B cells were seeded out per well in six-well plates. The following day, 1 µg of the passenger and 1 µg of the driver plasmid (pcDNA.L1-RP, pcDNA.ORF1, pcDNA.ORF2 or pcDNA.L1-RP (D702Y)) DNA was co-transfected into cells, using Fugene6 (Roche). 99 RPS EGFP Pur was also co-transfected with the driver plasmid DNA to normalize for co-transfection efficiency. In the experiments labeled FL-L1/2, cells were transfected with 1 µg of the passenger and 0.5 µg of the pcDNA.L1-RP plasmid DNA. For ORF1/ORF2 transfections, 1 µg of the passenger, 0.5 µg of pcDNA.ORF1 and 0.5 µg of pcDNA.ORF2 were co-transfected. Two days after transfection, puromycin was added to the media in order to select for cells transfected with the passenger plasmid. Puromycin was efficient at selecting transfected cells within 2 days after being added to the media. Five days after transfection, cells were harvested, washed and subjected to flow cytometry on a FACSCalibur machine. The gate was set for flow cytometry with cells co-transfected with SVA.10 EGFP and pcDNA.L1-RP (D702Y). We routinely counted approximately 100 000 cells per transfection. All transfections were performed in triplicate, except SVA.10R EGFP Δ 3TR and SVA.10 EGFP/ORF1/ORF2 in HeLa HA cells. The %EGFP-positive was calculated as the number of EGFP-positive cells divided by the number of transfected cells.

Inverse PCR

Genomic DNA (0.5 µg) isolated from cell lines generated from individual foci was digested for 4 h to overnight with *SacI*, *PpuMI* or *HindIII* (New England Biolabs) in a total reaction volume of 50 µl. The reaction was heat-inactivated by incubating at 65°C for 20 min. The digested DNA was ligated using T4 DNA ligase (New England Biolabs) in a total volume of 500 µl at 16°C for at least 16 h. DNA ligase was heat-inactivated at 65°C for 20 min. The DNA was ethanol-precipitated and resuspended in a total volume of 50 µl. PCR was performed using Ex Taq (Takara) according

to manufacturer's instructions with 1 μ l from the ligation reaction used as template. Nested PCR was carried out using 1 μ l of the first-round PCR diluted 200 \times . PCR products were resolved on 1% agarose gels. Bands of interest were excised and purified using the QIAquick Gel Extraction Kit (QIAGEN). Purified products were either sequenced directly by the Sanger method or TOPO (Invitrogen) cloned followed by sequencing. DNA sequences were checked for appropriate digestion followed by ligation at the expected restriction site. Genomic locations of SVA inserts were determined relative to the current human genome reference assembly (hg19/NCBI37) using the UCSC genome browser (85).

SUPPLEMENTARY MATERIAL

Supplementary Material is available at *HMG* online.

ACKNOWLEDGEMENTS

We thank members of the University of Pennsylvania School of Medicine and the Core DNA Analysis Facility at Johns Hopkins School of Medicine for DNA sequencing assistance. We would like to thank Dr John Moran for the HA-HeLa cells and CEP L1.3 ORF2 no *neo*, Dr Thierry Heidmann for the *Alu neo*^{Tet} plasmid and Dr Jose Garcia-Perez for the EGFP *mneoI* construct. We thank two anonymous reviewers for comments and suggestions that helped improve this manuscript. Likewise, we thank David Sigmon for excellent technical assistance and Adam Ewing for comments on this manuscript and insight throughout the project. Finally, we are grateful to past members of the Kazazian laboratory that worked on SVA over the years, in particular Dr Eric Ostertag, who cloned the SRE.1 *mneoI* construct.

Conflict of Interest statement. None declared.

FUNDING

This work was supported by a National Institutes of Health grant to H.H.K., Jr. D.C.H was funded in part by a genetics training grant, T32-GM008216-23, from the National Institutes of Health.

REFERENCES

- Lander, E., Linton, L., Birren, B., Nusbaum, C., Zody, M., Baldwin, J., Devon, K., Dewar, K., Doyle, M. and FitzHugh, W. (2001) Initial sequencing and analysis of the human genome. *Nature*, **409**, 860–921.
- Cordaux, R. and Batzer, M.A. (2009) The impact of retrotransposons on human genome evolution. *Nat. Rev. Genet.*, **10**, 691–703.
- Kazazian, H.H. Jr, Wong, C., Youssoufian, H., Scott, A.F., Phillips, D.G. and Antonarakis, S.E. (1988) Haemophilia A resulting from *de novo* insertion of L1 sequences represents a novel mechanism for mutation in man. *Nature*, **332**, 164–166.
- Wallace, M.R., Andersen, L.B., Saulino, A.M., Gregory, P.E., Glover, T.W. and Collins, F.S. (1991) A *de novo* Alu insertion results in neurofibromatosis type 1. *Nature*, **353**, 864–866.
- Ostertag, E.M., Goodier, J.L., Zhang, Y. and Kazazian, H.H. Jr (2003) SVA elements are nonautonomous retrotransposons that cause disease in humans. *Am. J. Hum. Genet.*, **73**, 1444–1451.
- Beck, C.R., Collier, P., Macfarlane, C., Malig, M., Kidd, J.M., Eichler, E.E., Badge, R.M. and Moran, J.V. (2010) LINE-1 retrotransposition activity in human genomes. *Cell*, **141**, 1159–1170.
- Ewing, A.D. and Kazazian, H.H. (2010) High-throughput sequencing reveals extensive variation in human-specific L1 content in individual human genomes. *Genome Res.*, **20**, 1262–1270.
- Huang, C.R.L., Schneider, A.M., Lu, Y., Niranjana, T., Shen, P., Robinson, M.A., Steranka, J.P., Valle, D., Civin, C.I., Wang, T. *et al.* (2010) Mobile interspersed repeats are major structural variants in the human genome. *Cell*, **141**, 1171–1182.
- Witherspoon, D., Xing, J., Zhang, Y., Watkins, W.S., Batzer, M. and Jorde, L. (2010) Mobile element scanning (ME-Scan) by targeted high-throughput sequencing. *BMC Genomics*, **11**, 410.
- Kidd, J.M., Graves, T., Newman, T.L., Fulton, R., Hayden, H.S., Malig, M., Kallnick, J., Kaul, R., Wilson, R.K. and Eichler, E.E. (2010) A human genome structural variation sequencing resource reveals insights into mutational mechanisms. *Cell*, **143**, 837–847.
- Hormozdiari, F., Alkan, C., Ventura, M., Hajirasouliha, I., Malig, M., Hach, F., Yorukoglu, D., Dao, P., Bakhshi, M., Sahinalp, S.C. *et al.* (2011) Alu repeat discovery and characterization within human genomes. *Genome Res.*, published in advance 3 December 2010, **21**, 840–849. doi:10.1101/gr.115956.110.
- Iskow, R.C., McCabe, M.T., Mills, R.E., Torene, S., Pittard, W.S., Neuwald, A.F., Van Meir, E.G., Vertino, P.M. and Devine, S.E. (2010) Natural mutagenesis of human genomes by endogenous retrotransposons. *Cell*, **141**, 1253–1261.
- Ewing, A.D. and Kazazian, H.H. (2011) Whole-genome resequencing allows detection of many rare LINE-1 insertion alleles in humans. *Genome Res.*, published in advance 27 October 2010, **21**, 985–990. doi:10.1101/gr.114777.110.
- Pickeral, O.K., Makalowski, W., Boguski, M.S. and Boeke, J.D. (2000) Frequent human genomic DNA transduction driven by LINE-1 retrotransposition. *Genome Res.*, **10**, 411–415.
- Goodier, J.L., Ostertag, E.M. and Kazazian, H.H. Jr (2000) Transduction of 3'-flanking sequences is common in L1 retrotransposition. *Hum. Mol. Genet.*, **9**, 653–657.
- Szak, S.T., Pickeral, O.K., Makalowski, W., Boguski, M.S., Landsman, D. and Boeke, J.D. (2002) Molecular archeology of L1 insertions in the human genome. *Genome Biol.*, **3**, research0052.
- Sen, S.K., Huang, C.T., Han, K. and Batzer, M.A. (2007) Endonuclease-independent insertion provides an alternative pathway for L1 retrotransposition in the human genome. *Nucleic Acids Res.*, **35**, 3741–3751.
- Srikanta, D., Sen, S.K., Huang, C.T., Conlin, E.M., Rhodes, R.M. and Batzer, M.A. (2009) An alternative pathway for Alu retrotransposition suggests a role in DNA double-strand break repair. *Genomics*, **93**, 205–212.
- Han, K., Lee, J., Meyer, T.J., Remedios, P., Goodwin, L. and Batzer, M.A. (2008) L1 recombination-associated deletions generate human genomic variation. *Proc. Natl Acad. Sci. USA*, **105**, 19366–19371.
- Wang, H., Xing, J., Grover, D., Hedges, D.J., Han, K., Walker, J.A. and Batzer, M.A. (2005) SVA elements: a hominid-specific retroposon family. *J. Mol. Biol.*, **354**, 994–1007.
- Xing, J., Wang, H., Belancio, V.P., Cordaux, R., Deininger, P.L. and Batzer, M.A. (2006) Emergence of primate genes by retrotransposon-mediated sequence transduction. *Proc. Natl Acad. Sci. USA*, **103**, 17608–17613.
- Symer, D.E., Connelly, C., Szak, S.T., Caputo, E.M., Cost, G.J., Parmigiani, G. and Boeke, J.D. (2002) Human L1 retrotransposition is associated with genetic instability *in vivo*. *Cell*, **110**, 327–338.
- Wei, W., Gilbert, N., Ooi, S.L., Lawler, J.F., Ostertag, E.M., Kazazian, H.H., Boeke, J.D. and Moran, J.V. (2001) Human L1 retrotransposition: cis preference versus trans complementation. *Mol. Cell. Biol.*, **21**, 1429–1439.
- Moran, J.V., Holmes, S.E., Naas, T.P., DeBerardinis, R.J., Boeke, J.D. and Kazazian, H.H. Jr (1996) High frequency retrotransposition in cultured mammalian cells. *Cell*, **87**, 917–927.
- Dewannieux, M., Esnault, C. and Heidmann, T. (2003) LINE-mediated retrotransposition of marked Alu sequences. *Nat. Genet.*, **35**, 41–48.
- Esnault, C., Maestre, J. and Heidmann, T. (2000) Human LINE retrotransposons generate processed pseudogenes. *Nat. Genet.*, **24**, 363–367.

27. Comeaux, M.S., Roy-Engel, A.M., Hedges, D.J. and Deininger, P.L. (2009) Diverse cis factors controlling Alu retrotransposition: what causes Alu elements to die? *Genome Res.*, **19**, 545–555.
28. Bennett, E.A., Keller, H., Mills, R.E., Schmidt, S., Moran, J.V., Weichenrieder, O. and Devine, S.E. (2008) Active Alu retrotransposons in the human genome. *Genome Res.*, **18**, 1875–1883.
29. Morrish, T.A., Gilbert, N., Myers, J.S., Vincent, B.J., Stamato, T.D., Taccioli, G.E., Batzer, M.A. and Moran, J.V. (2002) DNA repair mediated by endonuclease-independent LINE-1 retrotransposition. *Nat. Genet.*, **31**, 159–165.
30. Morrish, T.A., Garcia-Perez, J.L., Stamato, T.D., Taccioli, G.E., Sekiguchi, J. and Moran, J.V. (2007) Endonuclease-independent LINE-1 retrotransposition at mammalian telomeres. *Nature*, **446**, 208–212.
31. Garcia-Perez, J.L., Doucet, A.J., Bucheton, A., Moran, J.V. and Gilbert, N. (2007) Distinct mechanisms for trans-mediated mobilization of cellular RNAs by the LINE-1 reverse transcriptase. *Genome Res.*, **17**, 602–611.
32. Garcia-Perez, J.L., Marchetto, M.C., Muotri, A.R., Coufal, N.G., Gage, F.H., O’Shea, K.S. and Moran, J.V. (2007) LINE-1 retrotransposition in human embryonic stem cells. *Hum. Mol. Genet.*, **16**, 1569–1577.
33. Garcia-Perez, J.L., Morell, M., Scheys, J.O., Kulpa, D.A., Morell, S., Carter, C.C., Hammer, G.D., Collins, K.L., O’Shea, K.S., Menendez, P. *et al.* (2010) Epigenetic silencing of engineered L1 retrotransposition events in human embryonic carcinoma cells. *Nature*, **466**, 769–773.
34. Rangwala, S.H. and Kazazian, H.H. Jr (2009) The L1 retrotransposition assay: a retrospective and toolkit. *Methods*, **9**, 219–226.
35. Gilbert, N., Lutz, S., Morrish, T.A. and Moran, J.V. (2005) Multiple fates of L1 retrotransposition intermediates in cultured human cells. *Mol. Cell. Biol.*, **25**, 7780–7795.
36. Gilbert, N., Lutz-Prigge, S. and Moran, J.V. (2002) Genomic deletions created upon LINE-1 retrotransposition. *Cell*, **110**, 315–325.
37. Ostertag, E.M., DeBerardinis, R.J., Goodier, J.L., Zhang, Y., Yang, N., Gerton, G.L. and Kazazian, H.H. (2002) A mouse model of human L1 retrotransposition. *Nat. Genet.*, **32**, 655–660.
38. Kano, H., Godoy, I., Courtney, C., Vetter, M.R., Gerton, G.L., Ostertag, E.M. and Kazazian, H.H. Jr (2009) L1 retrotransposition occurs mainly in embryogenesis and creates somatic mosaicism. *Genes Dev.*, **23**, 1303–1312.
39. Prak, E.T., Dodson, A.W., Farkash, E.A. and Kazazian, H.H. Jr (2003) Tracking an embryonic L1 retrotransposition event. *Proc. Natl Acad. Sci. USA*, **100**, 1832–1837.
40. Babushok, D.V., Ostertag, E.M., Courtney, C.E., Choi, J.M. and Kazazian, H.H. (2006) L1 integration in a transgenic mouse model. *Genome Res.*, **16**, 240–250.
41. An, W., Han, J.S., Wheelan, S.J., Davis, E.S., Coombes, C.E., Ye, P., Triplett, C. and Boeke, J.D. (2006) Active retrotransposition by a synthetic L1 element in mice. *Proc. Natl Acad. Sci. USA*, **103**, 18662–18667.
42. Muotri, A.R., Chu, V.T., Marchetto, M.C., Deng, W., Moran, J.V. and Gage, F.H. (2005) Somatic mosaicism in neuronal precursor cells mediated by L1 retrotransposition. *Nature*, **435**, 903–910.
43. Kobayashi, K., Nakahori, Y., Miyake, M., Matsumura, K., Kondo-Iida, E., Nomura, Y., Segawa, M., Yoshioka, M., Saito, K., Osawa, M. *et al.* (1998) An ancient retrotranspositional insertion causes Fukuyama-type congenital muscular dystrophy. *Nature*, **394**, 388–392.
44. Wilund, K.R., Yi, M., Campagna, F., Arca, M., Zuliani, G., Fellin, R., Ho, Y.-K., Garcia, J.V., Hobbs, H.H. and Cohen, J.C. (2002) Molecular mechanisms of autosomal recessive hypercholesterolemia. *Hum. Mol. Genet.*, **11**, 3019–3030.
45. Makino, S., Kaji, R., Ando, S., Tomizawa, M., Yasuno, K., Goto, S., Matsumoto, S., Tabuena, M.D., Maranon, E., Dantes, M. *et al.* (2007) Reduced neuron-specific expression of the TAF1 gene is associated with X-linked dystonia-parkinsonism. *Am. J. Hum. Genet.*, **80**, 393–406.
46. Takasu, M., Hayashi, R., Maruya, E., Ota, M., Imura, K., Kougo, K., Kobayashi, C., Saji, H., Ishikawa, Y., Asai, T. *et al.* (2007) Deletion of entire HLA-A gene accompanied by an insertion of a retrotransposon. *Tissue Antigens*, **70**, 144–150.
47. Rohrer, J., Minegishi, Y., Richter, D., Eguiguren, J. and Conley, M.E. (1999) Unusual mutations in Btk: an insertion, a duplication, an inversion, and four large deletions. *Clin. Immunol.*, **90**, 28–37.
48. Hassoun, H., Coetzer, T.L., Vassiliadis, J.N., Sahr, K.E., Maalouf, G.J., Saad, S.T., Catanzariti, L. and Palek, J. (1994) A novel mobile element inserted in the alpha spectrin gene: spectrin dayton. A truncated alpha spectrin associated with hereditary elliptocytosis. *J. Clin. Invest.*, **94**, 643–648.
49. Legoix, P., Sarkissian, H.D., Cazes, L., Giraud, S., Sor, F., Rouleau, G.A., Lenoir, G., Thomas, G. and Zucman-Rossi, J. (2000) Molecular characterization of germline NF2 gene rearrangements. *Genomics*, **65**, 62–66.
50. Akman, H.O., Davidzon, G., Tanji, K., MacDermott, E.J., Larsen, L., Davidson, M.M., Haller, R.G., Szczepaniak, L.S., Lehman, T.J.A., Hirano, M. *et al.* (2010) Neutral lipid storage disease with subclinical myopathy due to a retrotranspositional insertion in the PNPLA2 gene. *Neuromuscul. Disord.*, **20**, 397–402.
51. Ono, M., Kawakami, M. and Takezawa, T. (1987) A novel human nonviral retroposon derived from an endogenous retrovirus. *Nucleic Acids Res.*, **15**, 8725–8737.
52. Zhu, Z.B., Hsieh, S.L., Bentley, D.R., Campbell, R.D. and Volanakis, J.E. (1992) A variable number of tandem repeats locus within the human complement C2 gene is associated with a retroposon derived from a human endogenous retrovirus. *J. Exp. Med.*, **175**, 1783–1787.
53. Shen, L., Wu, L.C., Sanlioglu, S., Chen, R., Mendoza, A.R., Dangel, A.W., Carroll, M.C., Zipf, W.B. and Yu, C.Y. (1994) Structure and genetics of the partially duplicated gene RP located immediately upstream of the complement C4A and the C4B genes in the HLA class III region. Molecular cloning, exon–intron structure, composite retroposon, and breakpoint of gene duplication. *J. Biol. Chem.*, **269**, 8466–8476.
54. Strichman-Almashanu, L.Z., Lee, R.S., Onyango, P.O., Perlman, E., Flam, F., Frieman, M.B. and Feinberg, A.P. (2002) A genome-wide screen for normally methylated human CpG islands that can identify novel imprinted genes. *Genome Res.*, **12**, 543–554.
55. Han, K., Konkel, M.K., Xing, J., Wang, H., Lee, J., Meyer, T.J., Huang, C.T., Sandifer, E., Hebert, K., Barnes, E.W. *et al.* (2007) Mobile DNA in Old World monkeys: a glimpse through the rhesus macaque genome. *Science*, **316**, 238–240.
56. Kim, H.S., Wadekar, R.V., Takenaka, O., Hyun, B.H. and Crow, T.J. (1999) Phylogenetic analysis of a retroposon family in African great apes. *J. Mol. Evol.*, **49**, 699–702.
57. Hancks, D.C. and Kazazian, H.H. Jr (2010) SVA retrotransposons: evolution and genetic instability. *Semin. Cancer Biol.*, **20**, 234–245.
58. Ostertag, E.M. and Kazazian, H.H. Jr (2001) Twin priming: a proposed mechanism for the creation of inversions in L1 retrotransposition. *Genome Res.*, **11**, 2059–2065.
59. Hancks, D.C., Ewing, A.D., Chen, J.E., Tokunaga, K. and Kazazian, H.H. Jr (2009) Exon-trapping mediated by the human retrotransposon SVA. *Genome Res.*, **19**, 1983–1991.
60. Damert, A., Raiz, J., Horn, A.V., Lower, J., Wang, H., Xing, J., Batzer, M.A., Lower, R. and Schumann, G.G. (2009) 5′-transducing SVA retrotransposon groups spread efficiently throughout the human genome. *Genome Res.*, **19**, 1992–2008.
61. Bantysh, O.B. and Buzdin, A.A. (2009) Novel family of human transposable elements formed due to fusion of the first exon of gene MAST2 with retrotransposon SVA. *Biochemistry (Moscow)*, **74**, 1393–1399.
62. Freeman, J.D., Goodchild, N.L. and Mager, D.L. (1994) A modified indicator gene for selection of retrotransposition events in mammalian cells. *Biotechniques*, **17**, 46, 48, 49, 52.
63. Jensen, S. and Heidmann, T. (1991) An indicator gene for detection of germline retrotransposition in transgenic *Drosophila* demonstrates RNA-mediated transposition of the LINE I element. *EMBO J.*, **10**, 1927–1937.
64. Kimberland, M.L., Divoky, V., Prchal, J., Schwahn, U., Berger, W. and Kazazian, H.H. Jr (1999) Full-length human L1 insertions retain the capacity for high frequency retrotransposition in cultured cells. *Hum. Mol. Genet.*, **8**, 1557–1560.
65. Dombroski, B.A., Scott, A.F. and Kazazian, H.H. Jr (1993) Two additional potential retrotransposons isolated from a human L1 subfamily that contains an active retrotransposable element. *Proc. Natl Acad. Sci. USA*, **90**, 6513–6517.
66. Sassaman, D.M., Dombroski, B.A., Moran, J.V., Kimberland, M.L., Naas, T.P., DeBerardinis, R.J., Gabriel, A., Swergold, G.D. and Kazazian, H.H. Jr (1997) Many human L1 elements are capable of retrotransposition. *Nat. Genet.*, **16**, 37–43.
67. Bogerd, H.P., Wiegand, H.L., Hulme, A.E., Garcia-Perez, J.L., O’Shea, K.S., Moran, J.V. and Cullen, B.R. (2006) Cellular inhibitors of long

- interspersed element 1 and Alu retrotransposition. *Proc. Natl Acad. Sci. USA*, **103**, 8780–8785.
68. Esnault, C., Casella, J.F. and Heidmann, T. (2002) A *Tetrahymena thermophila* ribozyme-based indicator gene to detect transposition of marked retroelements in mammalian cells. *Nucleic Acids Res.*, **30**, e49.
 69. Wallace, N., Wagstaff, B.J., Deininger, P.L. and Roy-Engel, A.M. (2008) LINE-1 ORF1 protein enhances Alu SINE retrotransposition. *Gene*, **419**, 1–6.
 70. Mathias, S.L., Scott, A.F., Kazazian, H.H. Jr, Boeke, J.D. and Gabriel, A. (1991) Reverse transcriptase encoded by a human transposable element. *Science*, **254**, 1808–1810.
 71. Alisch, R.S., Garcia-Perez, J.L., Muotri, A.R., Gage, F.H. and Moran, J.V. (2006) Unconventional translation of mammalian LINE-1 retrotransposons. *Genes Dev.*, **20**, 210–224.
 72. Khazina, E. and Weichenrieder, O. (2009) Non-LTR retrotransposons encode noncanonical RRM domains in their first open reading frame. *Proc. Natl Acad. Sci. USA*, **106**, 731–736.
 73. Martin, S.L. (2006) The ORF1 protein encoded by LINE-1: structure and function during L1 retrotransposition. *J. Biomed. Biotechnol.*, **2006**, 1.
 74. Goodier, J.L., Zhang, L., Vetter, M.R. and Kazazian, H.H. Jr (2007) LINE-1 ORF1 protein localizes in stress granules with other RNA-binding proteins, including components of RNA interference RNA-induced silencing complex. *Mol. Cell. Biol.*, **27**, 6469–6483.
 75. Doucet, A.J., Hulme, A.E., Sahinovic, E., Kulpa, D.A., Moldovan, J.B., Kopera, H.C., Athanikar, J.N., Hasnaoui, M., Bucheton, A., Moran, J.V. *et al.* (2010) Characterization of LINE-1 ribonucleoprotein particles. *PLoS Genet.*, **6**, e1001150.
 76. Ostertag, E.M., Prak, E.T., DeBerardinis, R.J., Moran, J.V. and Kazazian, H.H. Jr (2000) Determination of L1 retrotransposition kinetics in cultured cells. *Nucleic Acids Res.*, **28**, 1418–1423.
 77. Kubo, S., Seleme, M.C., Soifer, H.S., Perez, J.L., Moran, J.V., Kazazian, H.H. Jr and Kasahara, N. (2006) L1 retrotransposition in nondividing and primary human somatic cells. *Proc. Natl Acad. Sci. USA*, **103**, 8036–8041.
 78. Brouha, B., Schustak, J., Badge, R.M., Lutz-Prigge, S., Farley, A.H., Moran, J.V. and Kazazian, H.H. Jr (2003) Hot L1s account for the bulk of retrotransposition in the human population. *Proc. Natl Acad. Sci. USA*, **100**, 5280–5285.
 79. Feng, Q., Moran, J.V., Kazazian, H.H. Jr and Boeke, J.D. (1996) Human L1 retrotransposon encodes a conserved endonuclease required for retrotransposition. *Cell*, **87**, 905–916.
 80. Jurka, J. (1997) Sequence patterns indicate an enzymatic involvement in integration of mammalian retrotransposons. *Proc. Natl Acad. Sci. USA*, **94**, 1872–1877.
 81. Cost, G.J., Feng, Q., Jacquier, A. and Boeke, J.D. (2002) Human L1 element target-primed reverse transcription *in vitro*. *EMBO J.*, **21**, 5899–5910.
 82. Stenberg, R.M., Thomsen, D.R. and Stinski, M.F. (1984) Structural analysis of the major immediate early gene of human cytomegalovirus. *J. Virol.*, **49**, 190–199.
 83. Belancio, V.P., Hedges, D.J. and Deininger, P. (2008) Mammalian non-LTR retrotransposons: for better or worse, in sickness and in health. *Genome Res.*, **18**, 343–358.
 84. Wei, W., Morrish, T.A., Alisch, R.S. and Moran, J.V. (2000) A transient assay reveals that cultured human cells can accommodate multiple LINE-1 retrotransposition events. *Anal. Biochem.*, **284**, 435–438.
 85. Kent, W., Sugnet, C., Furey, T., Roskin, K., Pringle, T., Zahler, A. and Haussler, D. (2002) The human genome browser at UCSC. *Genome Res.*, **12**, 996–1006.
 86. Crooks, G.E., Hon, G., Chandonia, J.-M. and Brenner, S.E. (2004) WebLogo: a sequence logo generator. *Genome Res.*, **14**, 1188–1190.